Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Safety and immunogenicity of a heterologous booster of protein subunit vaccine MVC-COV1901 after two doses of adenoviral vector vaccine AZD1222

Shu-Hsing Cheng, Yi-Chun Lin, Cheng-Pin Chen, Chien-Yu Cheng
doi: https://doi.org/10.1101/2021.12.10.21267574
Shu-Hsing Cheng
1Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
2School of Public Health, Taipei Medical University, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi-Chun Lin
1Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheng-Pin Chen
1Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
3Institute of Public Health, School of Medicine National Yang-Ming Chiao Tung University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chien-Yu Cheng
1Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
4School of Clinical Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: s841060@gm.ym.edu.tw
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

We report the interim safety and immunogenicity results in participants administrated with a booster dose of protein subunit vaccine MVC-COV1901 at 12 or 24 weeks after two doses of AZD1222 (ChAdOx1 nCoV-19). In subjects fully vaccinated with two doses of AZD1222, waning antibody immunity was apparent within six months of the second dose of AZD1222. At one month after the MVC-COV1901 booster dose, anti-SARS-CoV-2 spike IgG antibody titers and neutralizing antibody titers were 14- and 8.6-fold increased, respectively, when compared to the titer levels on the day of the booster dose. These interim results support the use of MVC-COV1901 as a heterologous booster for individuals vaccinated with AZD1222.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT05097053

Funding Statement

Medigen Vaccine Biologics Corporation and Centers for Disease Control, Ministry of Health and Welfare, Taiwan

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Medical Ethics and Institutional Review Board of Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan City, Taiwan.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted December 14, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Safety and immunogenicity of a heterologous booster of protein subunit vaccine MVC-COV1901 after two doses of adenoviral vector vaccine AZD1222
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Safety and immunogenicity of a heterologous booster of protein subunit vaccine MVC-COV1901 after two doses of adenoviral vector vaccine AZD1222
Shu-Hsing Cheng, Yi-Chun Lin, Cheng-Pin Chen, Chien-Yu Cheng
medRxiv 2021.12.10.21267574; doi: https://doi.org/10.1101/2021.12.10.21267574
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Safety and immunogenicity of a heterologous booster of protein subunit vaccine MVC-COV1901 after two doses of adenoviral vector vaccine AZD1222
Shu-Hsing Cheng, Yi-Chun Lin, Cheng-Pin Chen, Chien-Yu Cheng
medRxiv 2021.12.10.21267574; doi: https://doi.org/10.1101/2021.12.10.21267574

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (551)
  • Anesthesia (135)
  • Cardiovascular Medicine (1749)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (311)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (654)
  • Epidemiology (10789)
  • Forensic Medicine (8)
  • Gastroenterology (585)
  • Genetic and Genomic Medicine (2938)
  • Geriatric Medicine (286)
  • Health Economics (532)
  • Health Informatics (1920)
  • Health Policy (833)
  • Health Systems and Quality Improvement (743)
  • Hematology (291)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12503)
  • Intensive Care and Critical Care Medicine (685)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (324)
  • Neurology (2787)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (556)
  • Occupational and Environmental Health (597)
  • Oncology (1458)
  • Ophthalmology (441)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (380)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (362)
  • Primary Care Research (334)
  • Psychiatry and Clinical Psychology (2635)
  • Public and Global Health (5345)
  • Radiology and Imaging (1004)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (724)
  • Rheumatology (329)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)